Synthia Guimond1,2,3,4, Feng Gu1, Holly Shannon1,4, Sinead Kelly3,5, Luke Mike3, Gabriel A Devenyi6,7, M Mallar Chakravarty6,7, John A Sweeney8, Godfrey Pearlson9,10, Brett A Clementz11,12, Carol Tamminga13, Matcheri Keshavan3. 1. Department of Psychiatry, The Royal's Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada. 2. Department of Psychoeducation and Psychology, Université du Québec en Outaouais, Gatineau, QC, Canada. 3. Department of Psychiatry, Massachusetts Mental Health Center and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 4. Department of Neuroscience, Carleton University, Ottawa, ON, Canada. 5. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. Department of Psychiatry, McGill University, Montréal, QC, Canada. 7. Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada. 8. Department of Psychiatry, University of Cincinnati, Cincinnati, OH, USA. 9. Department of Psychiatry, Yale University, New Haven, CT, USA. 10. Department of Neuroscience, Yale University, New Haven, CT, USA. 11. Department of Psychology, BioImaging Research Center, University of Georgia, Athens, GA, USA. 12. Department of and Neuroscience, BioImaging Research Center, University of Georgia, Athens, GA, USA. 13. Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
Abstract
OBJECTIVE: Brain-based Biotypes for psychotic disorders have been developed as part of the B-SNIP consortium to create neurobiologically distinct subgroups within idiopathic psychosis, independent from traditional phenomenological diagnostic methods. In the current study, we aimed to validate the Biotype model by assessing differences in volume and shape of the amygdala and hippocampus contrasting traditional clinical diagnoses with Biotype classification. METHODS: A total of 811 participants from 6 sites were included: probands with schizophrenia (n = 199), schizoaffective disorder (n = 122), psychotic bipolar disorder with psychosis (n = 160), and healthy controls (n = 330). Biotype classification, previously developed using cognitive and electrophysiological data and K-means clustering, was used to categorize psychosis probands into 3 Biotypes, with Biotype-1 (B-1) showing reduced neural salience and severe cognitive impairment. MAGeT-Brain segmentation was used to determine amygdala and hippocampal volumetric data and shape deformations. RESULTS: When using Biotype classification, B-1 showed the strongest reductions in amygdala-hippocampal volume and the most widespread shape abnormalities. Using clinical diagnosis, probands with schizophrenia and schizoaffective disorder showed the most significant reductions of amygdala and hippocampal volumes and the most abnormal hippocampal shape compared with healthy controls. Biotype classification provided the strongest neuroanatomical differences compared with conventional DSM diagnoses, with the best discrimination seen using bilateral amygdala and right hippocampal volumes in B-1. CONCLUSION: These findings characterize amygdala and hippocampal volumetric and shape abnormalities across the psychosis spectrum. Grouping individuals by Biotype showed greater between-group discrimination, suggesting a promising approach and a favorable target for characterizing biological heterogeneity across the psychosis spectrum.
OBJECTIVE: Brain-based Biotypes for psychotic disorders have been developed as part of the B-SNIP consortium to create neurobiologically distinct subgroups within idiopathic psychosis, independent from traditional phenomenological diagnostic methods. In the current study, we aimed to validate the Biotype model by assessing differences in volume and shape of the amygdala and hippocampus contrasting traditional clinical diagnoses with Biotype classification. METHODS: A total of 811 participants from 6 sites were included: probands with schizophrenia (n = 199), schizoaffective disorder (n = 122), psychotic bipolar disorder with psychosis (n = 160), and healthy controls (n = 330). Biotype classification, previously developed using cognitive and electrophysiological data and K-means clustering, was used to categorize psychosis probands into 3 Biotypes, with Biotype-1 (B-1) showing reduced neural salience and severe cognitive impairment. MAGeT-Brain segmentation was used to determine amygdala and hippocampal volumetric data and shape deformations. RESULTS: When using Biotype classification, B-1 showed the strongest reductions in amygdala-hippocampal volume and the most widespread shape abnormalities. Using clinical diagnosis, probands with schizophrenia and schizoaffective disorder showed the most significant reductions of amygdala and hippocampal volumes and the most abnormal hippocampal shape compared with healthy controls. Biotype classification provided the strongest neuroanatomical differences compared with conventional DSM diagnoses, with the best discrimination seen using bilateral amygdala and right hippocampal volumes in B-1. CONCLUSION: These findings characterize amygdala and hippocampal volumetric and shape abnormalities across the psychosis spectrum. Grouping individuals by Biotype showed greater between-group discrimination, suggesting a promising approach and a favorable target for characterizing biological heterogeneity across the psychosis spectrum.
Authors: Aristotle N Voineskos; Julie L Winterburn; Daniel Felsky; Jon Pipitone; Tarek K Rajji; Benoit H Mulsant; M Mallar Chakravarty Journal: Hum Brain Mapp Date: 2015-05-09 Impact factor: 5.038
Authors: Matthew E Hudgens-Haney; Lauren E Ethridge; Jennifer E McDowell; Sarah K Keedy; Godfrey D Pearlson; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney; Brett A Clementz Journal: Schizophr Res Date: 2017-08-24 Impact factor: 4.939
Authors: Lanxin Ji; Shashwath A Meda; Carol A Tamminga; Brett A Clementz; Matcheri S Keshavan; John A Sweeney; Elliot S Gershon; Godfrey D Pearlson Journal: Schizophr Res Date: 2019-08-19 Impact factor: 4.939
Authors: Pamela B Mahon; David S Lee; Huong Trinh; Daniel Tward; Michael I Miller; Laurent Younes; Patrick E Barta; J Tilak Ratnanather Journal: Schizophr Res Date: 2015-03-09 Impact factor: 4.939
Authors: Richard S E Keefe; Terry E Goldberg; Philip D Harvey; James M Gold; Margaret P Poe; Leigh Coughenour Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: Carrie E Bearden; Paul M Thompson; Rebecca A Dutton; Benício N Frey; Marco A M Peluso; Mark Nicoletti; Nicole Dierschke; Kiralee M Hayashi; Andrea D Klunder; David C Glahn; Paolo Brambilla; Roberto B Sassi; Alan G Mallinger; Jair C Soares Journal: Neuropsychopharmacology Date: 2007-08-08 Impact factor: 7.853
Authors: C Makowski; M Bodnar; J J Shenker; A K Malla; R Joober; M M Chakravarty; M Lepage Journal: Transl Psychiatry Date: 2017-08-08 Impact factor: 6.222
Authors: Brett A Clementz; David A Parker; Rebekah L Trotti; Jennifer E McDowell; Sarah K Keedy; Matcheri S Keshavan; Godfrey D Pearlson; Elliot S Gershon; Elena I Ivleva; Ling-Yu Huang; S Kristian Hill; John A Sweeney; Olivia Thomas; Matthew Hudgens-Haney; Robert D Gibbons; Carol A Tamminga Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 9.306